Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Apr 13, 2022 2:06pm
127 Views
Post# 34601189

RE:RE:RE:RE:RE:Cash position

RE:RE:RE:RE:RE:Cash position It's worth remembering these are late stage cancer patients with less than 6 months of life expectancy often the last month or two they come of drugs due to wide spread metastasis and drug side effects so although it's not directly related to efficacy if they have been on the drug for a longer period of time for one the drug has good safety profile and secondly it might have extended their life due to efficacy and yes all we can speculate about for now is it MIGHT..
jfm1330 wrote: That's a lot of hinting don't you think? And again, you can see what you want in patient #2 . If that's a hint of efficacy, it's a very weak hint. You don't base an investment decision on that.


SPCEO1 wrote: TH has already hinted about hints of efficacy with patient #2. 




<< Previous
Bullboard Posts
Next >>